Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with
previously treated malignant mesothelioma.